MP28-21 MIRABEGRON FOR TREATMENT OF ERECTILE DYSFUNCTION CONCOMITANT WITH LOWER URINARY TRACT SYMPTOMS IN PATIENTS WITH BENIGN PROSTATIC HYPERPLASIA. A RANDOMIZED CONTROLLED TRIAL

Abstract

You have accessJournal of UrologyBenign Prostatic Hyperplasia: Epidemiology & Evaluation (MP28)1 Sep 2021MP28-21 MIRABEGRON FOR TREATMENT OF ERECTILE DYSFUNCTION CONCOMITANT WITH LOWER URINARY TRACT SYMPTOMS IN PATIENTS WITH BENIGN PROSTATIC HYPERPLASIA. A RANDOMIZED CONTROLLED TRIAL Ramy Elbaz, Ahmed El-assmy, Mohamed H. Zahran, Abdelwahab Hashem, and Ahmed A. Shokeir Ramy ElbazRamy Elbaz More articles by this author , Ahmed El-assmyAhmed El-assmy More articles by this author , Mohamed H. ZahranMohamed H. Zahran More articles by this author , Abdelwahab HashemAbdelwahab Hashem More articles by this author , and Ahmed A. ShokeirAhmed A. Shokeir More articles by this author View All Author Informationhttps://doi.org/10.1097/JU.0000000000002025.21AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: To assess the efficacy of mirabegron in treatment of erectile dysfunction (ED) that occurs in association with lower urinary tract symptoms (LUTS) in patients with benign prostatic hyperplasia (BPH). METHODS: This single-blinded randomized controlled trial (RCT) was approved by the local Institutional Review Board (IRB) committee (IRB number: 18.07.214). Fifty-five sexually active BPH patients between 50-70 years with concomitant ED and LUTS were randomly allocated in two groups: the first received mirabegron 50 mg plus doxazosin 2 mg once daily (mirabegron group) and the second one received tolterodine 4 mg plus doxazosin 2 mg once daily (tolterodine group). The evaluation of sexual dysfunctions and LUTS was based on International Index of Erectile Function (IIEF-15) questionnaire -and its five subdomains-, Erection Hardness Score (EHS) questionnaire, International Prostate Symptom Score (IPSS)- and its storage, voiding and QOL subdomains- uroflometry and post voiding residual (PVR) assessed by ultrasonography. The therapeutic outcomes were assessed at 4, and 12 weeks compared to the baseline. RESULTS: Only, mirabegron group achieved significant improvement in sexual functions after 4 and 12 weeks including IIEF-15 total score, its erectile function (EF) domain, intercourse satisfaction domain, overall satisfaction domain and EHS questionnaire. By using 5 points or more difference from the baseline as a cut-off point of change, there was significant difference in change direction of IIEF-15 total score in favor of mirabegron group, after 4 weeks, IIEF-15 total score decreased in 4.2%, unchanged in 16.7% and improved in 79.1% in mirabegron group compared to 13%, 69.6% and 17.4%, respectively in tolterodine group (p <0.001), also, this significant difference between both groups was maintained after 12 weeks. Regarding the urinary characteristics, both group showed significant improvement in IPSS total score, its storage subdomain, QOL subdomain and PVR at both 4th and 12th week. In mirabegron group, IPSS total score improved from 18±6 at baseline to 12±4.6 and 11.±4.8 after 4 and 12 weeks, respectively (p <0.001), in tolterodine group, it improved from 17±5 at baseline to 13.7±4.4 and 12±5 after 4 and 12 weeks, respectively (p <0.001). However, only mirabegron group achieved significant improvement in voiding subdomain and Q max after both 4th and 12th week. CONCLUSIONS: Mirabegron –a β3 agonist- not only improves urinary characteristics in patients with LUTS secondary to BPH but also improves significantly the associated sexual and erectile characteristics. Source of Funding: Not present © 2021 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 206Issue Supplement 3September 2021Page: e489-e489 Advertisement Copyright & Permissions© 2021 by American Urological Association Education and Research, Inc.MetricsAuthor Information Ramy Elbaz More articles by this author Ahmed El-assmy More articles by this author Mohamed H. Zahran More articles by this author Abdelwahab Hashem More articles by this author Ahmed A. Shokeir More articles by this author Expand All Advertisement Loading ...